Thrombocytopenia in neonates and the risk of intraventricular hemorrhage: a retrospective cohort study

Jeannette S von Lindern, Tjitske van den Bruele, Enrico Lopriore, Frans J Walther, Jeannette S von Lindern, Tjitske van den Bruele, Enrico Lopriore, Frans J Walther

Abstract

Background: The overall prevalence of thrombocytopenia in neonates admitted to neonatal intensive care units ranges from 22 to 35%. There are only a few small studies that outline the relationship between the severity of thrombocytopenia and the risk of bleeding. This makes it difficult to form an evidence-based threshold for platelet transfusions in neonatal patients. The aim of this study was to determine the prevalence of thrombocytopenia in a tertiary neonatal intensive care unit and to study the relation between thrombocytopenia and the risk of intraventricular hemorrhage (IVH).

Methods: We performed a retrospective cohort study of all patients with thrombocytopenia admitted to our neonatal tertiary care nursery between January 2006 and December 2008. Patients were divided into 4 groups according to the severity of thrombocytopenia: mild (100-149 × 109/L), moderate (50-99 × 109/L), severe (30-49 × 109/L) or very severe (< 30 × 109/L). The primary outcome was IVH ≥ grade 2. Pearson's chi-squared and Fischer's exact tests were used for categorical data. ANOVA, logistic regression analysis and multivariate linear regression were used for comparisons between groups and for confounding factors.

Results: The prevalence of thrombocytopenia was 27% (422/1569). Risk of IVH ≥ grade 2 was 12% (48/411) in neonates with versus 5% (40/844) in neonates without thrombocytopenia (p < 0.01). After multivariate linear regression analysis, risk of IVH ≥ grade 2 in the subgroups of thrombocytopenic infants was not significantly different (p = 0.3).After logistic regression analysis the difference in mortality rate in neonates with and without thrombocytopenia was not significant (p = 0.4). Similarly, we found no difference in mortality rate in the subgroups of neonates with thrombocytopenia (p = 0.7).

Conclusion: Although IVH ≥ grade 2 occurs more often in neonates with thrombocytopenia, this relation is independent of the severity of thrombocytopenia. Prospective studies should be conducted to assess the true risk of hemorrhage depending on underlying conditions. Randomized controlled trials are urgently needed to determine a safe lower threshold for platelet transfusions.

Figures

Figure 1
Figure 1
Flow-chart of all in- and exclusions of the cohort.

References

    1. Roberts I, Stanworth S, Murray NA. Thrombocytopenia in the neonate. Blood Rev. 2008;22:173–186. doi: 10.1016/j.blre.2008.03.004.
    1. Sola-Visner M, Saxonhouse MA, Brown RE. Neonatal thrombocytopenia: what we do and don't know. Early Hum Dev. 2008;84:499–506. doi: 10.1016/j.earlhumdev.2008.06.004.
    1. Sola MC, Rimsza LM. Mechanisms underlying thrombocytopenia in the neonatal intensive care unit. Acta Paediatr Suppl. 2002;91:66–73. doi: 10.1080/080352502320764210.
    1. Christensen RD. Advances and controversies in neonatal ICU platelet transfusion practice. Adv Pediatr. 2008;55:255–269. doi: 10.1016/j.yapd.2008.07.003.
    1. Del Vecchio A, Sola MC, Theriaque DW, Hutson AD, Kao KJ, Wright D. et al.Platelet transfusions in the neonatal intensive care unit:factors predicting which patients will require multiple transfusions. Transfusion. 2001;41:803–808. doi: 10.1046/j.1537-2995.2001.41060803.x.
    1. Roberts I, Murray NA. Neonatal thrombocytopenia. Semin Fetal Neonatal Med. 2008;13:256–264. doi: 10.1016/j.siny.2008.02.004.
    1. Bizzozero J. Über einen neuen formbestandteil des blutes und dessen rolle bei der thrombose und blutgerinnung. Virchow's Arch Path Anat Physiol Klin Med. 1882;90:261–332.
    1. Andrew M, Castle V, Saigal S, Carter C, Kelton JG. Clinical impact of neonatal thrombocytopenia. J Pediatr. 1987;110:457–464. doi: 10.1016/S0022-3476(87)80517-6.
    1. Andrew M, Vegh P, Caco C, Kirpalani H, Jefferies A, Ohlsson A. et al.A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants. J Pediatr. 1993;123:285–291. doi: 10.1016/S0022-3476(05)81705-6.
    1. Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122:10–23. doi: 10.1046/j.1365-2141.2003.04468.x.
    1. Delaney M, Meyer E, Cserti-Gazdewich C, Haspel RL, Lin Y, Morris A. et al.A systematic assessment of the quality of reporting for platelet transfusion studies. Transfusion. 2010;50:2135–2144. doi: 10.1111/j.1537-2995.2010.02691.x.
    1. Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med. 2002;30:1765–1771. doi: 10.1097/00003246-200208000-00015.
    1. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG. et al.Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362:600–613. doi: 10.1056/NEJMoa0904084.
    1. Het Kwaliteitsinstituut voor de Gezondheidszorg CBO. CBO-richtlijn bloedtransfusies. Alphen aan den Rijn, Van Zuiden Communications B.V. 2004. pp. 247–257.
    1. Murray NA, Howarth LJ, McCloy MP, Letsky EA, Roberts IA. Platelet transfusion in the management of severe thrombocytopenia in neonatal intensive care unit patients. Transfus Med. 2002;12:35–41. doi: 10.1046/j.1365-3148.2002.00343.x.
    1. Sola MC. Evaluation and treatment of severe and prolonged thrombocytopenia in neonates. Clin Perinatol. 2004;31:1–14. doi: 10.1016/j.clp.2004.03.014.
    1. von Lindern JS, Brand A. The use of blood products in perinatal medicine. Semin Fetal Neonatal Med. 2008;13:272–281. doi: 10.1016/j.siny.2008.03.001.
    1. Volpe JJ. Neurology of the newborn. 5. Philadelphia: Saunders Elsevier; 2008.
    1. Kloosterman GJ. [Intrauterine growth and intrauterine growth curves] Ned Tijdschr Verloskd Gynaecol. 1969;69:349–365.
    1. Neu J. Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention. Pediatr Clin North Am. 1996;43:409–432. doi: 10.1016/S0031-3955(05)70413-2.
    1. Bonifacio L, Petrova A, Nanjundaswamy S, Mehta R. Thrombocytopenia related neonatal outcome in preterms. Indian J Pediatr. 2007;74:269–274. doi: 10.1007/s12098-007-0042-x.
    1. Stanworth SJ, Bennett C. How to tackle bleeding and thrombosis in the newborn. Early Hum Dev. 2008;84:507–513. doi: 10.1016/j.earlhumdev.2008.06.006.
    1. Baer VL, Lambert DK, Henry E, Christensen RD. Severe Thrombocytopenia in the NICU. Pediatrics. 2009;124:e1095–e1100. doi: 10.1542/peds.2009-0582.
    1. Stanworth SJ, Clarke P, Watts T, Ballard S, Choo L, Morris T. et al.Prospective, Observational Study of Outcomes in Neonates With Severe Thrombocytopenia. Pediatrics. 2009;124(5):e826–34. doi: 10.1542/peds.2009-0332.
    1. Sola-Visner M, Sallmon H, Brown R. New insights into the mechanisms of nonimmune thrombocytopenia in neonates. Semin Perinatol. 2009;33:43–51. doi: 10.1053/j.semperi.2008.10.008.
    1. New HV, Stanworth SJ, Engelfriet CP, Reesink HW, McQuilten ZK, Savoia HF. et al.Neonatal transfusions. Vox Sang. 2009;96:62–85. doi: 10.1111/j.1423-0410.2008.01105.x.
    1. Josephson CD, Su LL, Christensen RD, Hillyer CD, Castillejo MI, Emory MR. et al.Platelet transfusion practices among neonatologists in the United States and Canada: results of a survey. Pediatrics. 2009;123:278–285. doi: 10.1542/peds.2007-2850.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅